Compounds > pargyline
Page last updated: 2024-11-02

pargyline and ADDH

pargyline has been researched along with ADDH in 2 studies

Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wender, PH2
Wood, DR2
Reimherr, FW2
Ward, M1

Trials

1 trial available for pargyline and ADDH

ArticleYear
An open trial of pargyline in the treatment of attention deficit disorder, residual type.
    Psychiatry research, 1983, Volume: 9, Issue:4

    Topics: Adult; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Female; Humans; Male

1983

Other Studies

1 other study available for pargyline and ADDH

ArticleYear
Pharmacological treatment of attention deficit disorder, residual type (ADD,RT, "minimal brain dysfunction," "hyperactivity") in adults.
    Psychopharmacology bulletin, 1985, Volume: 21, Issue:2

    Topics: Adult; Attention Deficit Disorder with Hyperactivity; Humans; Methylphenidate; Pargyline; Pemoline;

1985